Kumar Ramdas, MD
Internal Medicine · Maplewood, NJNPI 1780663898
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $66,705 of the $86,582 with a category attached, or 77.0%. 60 manufacturers reported payments, led by AbbVie at 48.8% of the total. Reporting peaked in 2020 at $41,390 and has fallen 93.0% since, to $2,895 in 2025. Among internal medicine clinicians in NJ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 1,131 payments — averaging $76.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$42K
- GSK$20K
- Johnson & Johnson$10K
- AstraZeneca$3K
- Boehringer Ingelheim$1K
- Lilly USA, LLC$1K
- plus $9K from 54 others
What the payments were for
- Speaking & faculty fees$66,70577%
- Travel & lodging$6811%
- Food & beverage$18,89622%
- Education$2000%
- Gifts$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- UBRELVY$22,742
- TRELEGY ELLIPTA$19,818
- VRAYLAR$12,474
- INVOKANA$9,321
- Creon$4,575
- REZDIFFRA$660
- JARDIANCE$365
- Humira$246
- HawkOne$165
- VOQUEZNA$125
- SOLIQUA 100/33$121
- XARELTO$120
- Reltone 200 Mg$100
- Reltone 400 Mg$100
How this compares
$86,582 in reported general payments places this provider in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 690 | $257,981 |
| MounjaroTirzepatide | 203 | $240,748 |
| FarxigaDapagliflozin Propanediol | 286 | $191,389 |
| TrulicityDulaglutide | 196 | $176,781 |
| JardianceEmpagliflozin | 220 | $141,506 |
| JanuviaSitagliptin Phosphate | 259 | $133,074 |
| LinzessLinaclotide | 170 | $96,523 |
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 20 | $84,168 |
| RukobiaFostemsavir Tromethamine | 25 | $79,555 |
| VascepaIcosapent Ethyl | 190 | $73,149 |
| MyrbetriqMirabegron | 152 | $63,766 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 83 | $62,650 |
| XareltoRivaroxaban | 136 | $59,637 |
| TivicayDolutegravir Sodium | 27 | $55,340 |
| Diclofenac Sodium | 248 | $53,731 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity | $1,428 | $417,530399 claims |
| PfizerEliquis | $272 | $257,981690 claims |
| Boehringer IngelheimJardiance, Tradjenta, Synjardy Xr, Synjardy, Jentadueto | $1,465 | $252,472390 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $2,619 | $243,075342 claims |
| MerckJanuvia, Janumet | $965 | $165,873309 claims |
| AbbVieLinzess, Vraylar, Creon | $42,213 | $130,348198 claims |
| GileadBiktarvy | $27 | $84,16820 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $20,178 | $79,711125 claims |
| Astellas Pharma US IncMyrbetriq | $178 | $63,766152 claims |
| Johnson & JohnsonXarelto | $9,912 | $59,637136 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $205 | $33,11433 claims |
| NovartisEntresto | $575 | $32,63186 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,032 internal medicine providers in New Jersey.
Other internal medicine in Maplewood
- David ShulkinMorristown$1.7M
- Howard UdermanLakewood$955K
- Darshi SunderamEast Orange$530K
- Annika DrongeEmerson$401K
- Stephen MarcellaNew Brunswick$331K
- Viju VijaysadanKinnelon$325K
- Mark MonaneWoodcliff Lake$268K
- Martin BedigianLivingston$240K
- Rameck HuntPlainsboro$217K
- Angel LazoSecaucus$195K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.